Skip to main content
PlainMeds

Prescription medicine

Nogapendekin alfa inbakicept-pmln Brand names: Anktiva

Nogapendekin alfa inbakicept-pmln (Anktiva) is a prescription medicine with an FDA approval on record since 2024. No generic is listed in FDA's NDC Directory.

  • No generic listed

Check it at the source: the nogapendekin alfa inbakicept-pmln FDA label on DailyMed (effective June 24, 2025, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.); the BLA 761336 record on Drugs@FDA; every nogapendekin alfa inbakicept-pmln label on DailyMed.

Highlights of the record

FDA label of June 24, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage

ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Forms and strengths

  • 0.4ml

Solution.

On the market

Earliest approval on file
April 22, 2024 Anktiva, Altor Bioscience, Llc, An Indirect Wholly-Owned Su; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals
No generic approved
Labelers listed (NDC)
1 of which 0 under generic applications, 1 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC)
Not in the survey
Shortage (FDA)
No current entry
Recalls by its makers (FDA)
No recall recorded
FAERS reports
36 through July 30, 2026

What is nogapendekin alfa inbakicept-pmln used for?

From the label: indications and usage

ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

FDA pharmacologic class: Interleukin-15 Receptor Agonist.

Source: FDA drug label (ANKTIVA), Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., effective June 24, 2025 (SPL set eae31db8-3e7a-d9e0-708d-74419d1b50ff), via openFDA; the full label on DailyMed

Is there a generic for nogapendekin alfa inbakicept-pmln (Anktiva)?

No generic nogapendekin alfa inbakicept-pmln is approved (Drugs@FDA, October 8, 2026).

  • 2024 earliest approval on file

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do FAERS reports show for nogapendekin alfa inbakicept-pmln?

The FDA Adverse Event Reporting System holds 36 reports that list nogapendekin alfa inbakicept-pmln among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 7 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

  • Neutropenia10
  • Chills (named in the label)6
  • Pyrexia (named in the label)6
  • Anaemia4
  • Bladder Pain3
  • Dysuria (named in the label)3
  • Nausea (named in the label)3
  • Pollakiuria3

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Nogapendekin alfa inbakicept-pmln side effects
the label's list beside FAERS reports
Check an interaction
what two or more labels say about each other